Acrux Limited (AU:ACR) has released an update.
Acrux Limited has commenced the commercial launch of its Nitroglycerin Ointment, 0.4% in the U.S., marking the company’s fourth product in the American market. This FDA-approved generic version of Rectiv® is aimed at treating chronic anal fissure pain and taps into a growing market exceeding $23 million. The launch strengthens Acrux’s strategy to expand its pipeline of topical products.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.